These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27683456)

  • 1. Mechanisms of Androgen-Independent Prostate Cancer.
    Saraon P; Drabovich AP; Jarvi KA; Diamandis EP
    EJIFCC; 2014 Apr; 25(1):42-54. PubMed ID: 27683456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations during progression of prostate cancer to androgen independence.
    Saraon P; Jarvi K; Diamandis EP
    Clin Chem; 2011 Oct; 57(10):1366-75. PubMed ID: 21956922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
    Taplin ME; Balk SP
    J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.
    Powell SM; Christiaens V; Voulgaraki D; Waxman J; Claessens F; Bevan CL
    Endocr Relat Cancer; 2004 Mar; 11(1):117-30. PubMed ID: 15027889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Androgen Receptor in Prostate Cancer: A Review.
    Fujita K; Nonomura N
    World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Molecular Evolution of Castration-resistant Prostate Cancer.
    Ceder Y; Bjartell A; Culig Z; Rubin MA; Tomlins S; Visakorpi T
    Eur Urol Focus; 2016 Dec; 2(5):506-513. PubMed ID: 28723516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
    Scher HI; Buchanan G; Gerald W; Butler LM; Tilley WD
    Endocr Relat Cancer; 2004 Sep; 11(3):459-76. PubMed ID: 15369448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy.
    Zhang KX; Firus J; Prieur B; Jia W; Rennie PS
    Cancers (Basel); 2011 Mar; 3(2):1498-512. PubMed ID: 24212771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges.
    Kita Y; Goto T; Akamatsu S; Yamasaki T; Inoue T; Ogawa O; Kobayashi T
    Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30248934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
    Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
    Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor as a target in androgen-independent prostate cancer.
    Balk SP
    Urology; 2002 Sep; 60(3 Suppl 1):132-8; discussion 138-9. PubMed ID: 12231070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the androgen receptor in the development and progression of prostate cancer.
    Jenster G
    Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
    Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
    Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
    Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.